002294 · SZSE · China
salubris.comFinancials as of FY2024 · latest on file
Makes and sells approved cardiovascular, antibiotic, orthopedic, and CNS drugs to Chinese hospitals from one Shenzhen factory.
Shenzhen Salubris Pharmaceuticals makes finished drugs across four therapeutic categories — cardiovascular, antibiotic, orthopedic, and CNS — all manufactured inside a single facility in Shenzhen that holds active NMPA licences for each one. Every product the company can legally sell is defined by which registrations have already cleared that facility, and each new registration requires its own 2-3 year clinical and bioequivalence review that no amount of spending can shorten, so the portfolio grows slowly and on a regulatory calendar rather than a commercial one. Because NMPA bioequivalence certifications are tied to the specific facility and cannot be transferred, hospitals and provincial reimbursement programs that already list these products have no approved domestic substitute they can switch to within a normal contract cycle, which locks the company into the sales channel as tightly as the sales channel is locked into the company. The same concentration that makes this arrangement durable is also what makes it fragile: a single enforcement action by the NMPA against the Shenzhen facility — a contamination finding, a GMP revocation — would suspend every approved product at once, with no legal path to resume supply until each indication completed a fresh 2-3 year registration from scratch.
How does this company make money?
The company earns money each time a finished drug is sold to a Chinese hospital procurement department, a pharmacy chain, or a medical distributor. The price it receives is not set through direct negotiation — it is determined by government tender processes and provincial reimbursement schedules. Selling more units of already-approved drugs is the main way revenue grows.
What makes this company hard to replace?
Hospital procurement contracts in China typically run on 2-3 year cycles, and rebidding processes favor suppliers who already hold NMPA approval for the same facility. Even if a hospital wanted to switch to a different manufacturer mid-cycle, NMPA bioequivalence certifications cannot be transferred — the replacement supplier would have to run entirely new clinical studies and wait for its own approval. Provincial health insurance reimbursement listings create an additional layer: hospitals face administrative barriers if they try to substitute a product that is not already listed as an approved alternative.
What limits this company?
Adding a new drug to the portfolio requires running fresh clinical and bioequivalence studies and waiting 2-3 years for NMPA review. That clock cannot be sped up with money, and two different drugs cannot go through the process at the same time and both arrive faster. So the number of new products the company can launch in any given window is fixed by the regulatory calendar, not by how much factory space or funding it has.
What does this company depend on?
The company cannot run without active pharmaceutical ingredients from Chinese specialty chemical manufacturers, NMPA manufacturing licences for pharmaceutical production in Guangdong Province, Good Manufacturing Practice certification for each of its four therapeutic production lines, import permits for any raw materials sourced outside China, and ongoing compliance with Chinese pharmacopoeia standards for every formulation it produces.
Who depends on this company?
Chinese hospital procurement departments rely on the company's cardiovascular and antibiotic products to keep their formularies stocked — if supply stopped, those drug options would simply be unavailable for the length of a new approval cycle. Provincial health insurance programs depend on domestic pharmaceutical availability to populate their reimbursement catalogs. Chinese pharmacy chains depend on locally-manufactured generics to maintain the margins they earn as alternatives to imported drugs.
How does this company scale?
Once a production line is running, it can push out higher volumes of the same approved formulation with very little extra labor cost — that part scales easily. What does not scale is the approval side: every new therapeutic indication needs its own clinical studies, its own bioequivalence trials, and its own NMPA review, none of which can be parallelized or handed off to someone else to run faster.
What external forces can significantly affect this company?
The Chinese government sets price ceilings on essential medicines through centralized procurement policies, which directly limits how much margin the company can earn per unit. If the yuan weakens against other currencies, the cost of any imported raw materials rises while the company's renminbi-denominated sales revenue stays flat. On the positive side, China's aging population is pushing regulators to favor domestically-manufactured chronic disease medications, which benefits a company already holding those approvals.
Where is this company structurally vulnerable?
If China's National Medical Products Administration suspended the Shenzhen facility's licence — because of a contamination finding, a GMP revocation, or any other enforcement action — all four therapeutic categories would lose their manufacturing authorization at the same moment. Because NMPA bioequivalence certifications are tied to that specific facility and cannot be handed to another manufacturer, no replacement supplier could legally make the same approved drugs without restarting the full 2-3 year registration process for every single indication.
Sign in to view price data.
Sign inScreen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph